Hence, R-flurbiprofen, likely acts as an inhibitor of these ABC transporters, and thereby may reduce tumor growth; however, unfortunately, in clinical studies of prostate cancer, R-flurbiprofen failed despite the well-documented beneficial effects of COX inhibition in cancer patients [50,51]. The gene discussed is ABCG2; the disease is cancer.